About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Up 0.05 (0.56%)
Data as of 04/28/17 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $9.05 with a 52 week high of $13.80 and a 52 week low of $7.35.

Recent News

Study in Nature Shows Early Relapse Detection in Lung Cancer Using Natera's Technology for ctDNA Analysis - 04/26/17
Relapse detected up to 347 days earlier than standard of care, with sensitivity and specificity exceeding 90% SAN CARLOS, Calif. and LONDON, April 26, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, a... More»
Natera Reports Fourth Quarter and Fiscal Year 2016 Financial Results - 03/07/17
SAN CARLOS, Calif., March 7, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and fiscal year ended... More»
Natera, Inc. Announces Launch of Evercord™ Cord Blood and Tissue Banking Service - 03/01/17
Launch Expands Natera's Leadership Position in Women's Reproductive Health SAN CARLOS, Calif., March 1, 2017 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in genetic testing, today announced the upcoming launch of Evercord; a new offering being... More»
Natera Inc. Announces Fourth Quarter and Fiscal Year 2016 Earnings Conference Call - 02/28/17
SAN CARLOS, Calif., Feb. 28, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended Decemb... More»
Natera Inc. Announces Appointment of Mike Brophy as New Chief Financial Officer - 02/03/17
Former Chief Financial Officer Herm Rosenman to Join Natera's Board of Directors SAN CARLOS, Calif., Feb. 3, 2017 /PRNewswire/ -- Natera Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced today the appointment of Mike Broph... More»

Upcoming Events

There are currently no events scheduled.

Recent Presentations

There are currently no items available.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools